CM&R Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Medicine & Research
Volume 1, Number 2 : 101 -104
doi:
© 2003 Marshfield Clinic
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rezkalla, S. H.
Right arrow Articles by Benz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rezkalla, S. H.
Right arrow Articles by Benz, M.

Review

Antiplatelet Therapy from Clinical Trials to Clinical Practice

Shereif H. Rezkalla, MD

Department of Cardiology, Marshfield Clinic, Marshfield, Wisconsin

Michele Benz

Department of Cardiology, Marshfield Clinic, Marshfield, Wisconsin

REPRINT REQUESTS: Shereif H. Rezkalla, MD, Department of Cardiology, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, WI 54449, Telephone: 715-387-5301, Fax: 715-389-3808, Email: rezkalla.shereif{at}marshfieldclinic.org

A platelet-rich clot at the site of severe coronary stenosis, plaque erosion, or a recent plaque rupture is the common etiology of acute ischemic syndromes. Thus, antiplatelet therapy is the cornerstone in the management of these conditions. Aspirin in a dose ranging from 160 to 325 mg once daily should be administered to virtually all patients. In patients with severe disease, particularly those who have no acute angiography, clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi Pharmaceuticals) in a dose of 75 mg once daily should add to the benefit of aspirin for up to a year after the event. Clopidogrel also is an alternative to aspirin where a true aspirin allergy exists. Intravenous platelet glycoprotein IIb/IIIa receptor inhibitors demonstrated a robust benefit when used in conjunction with coronary intervention and thus far have no role in medical therapy alone. Oral platelet glycoprotein IIb/IIIa receptor inhibitors are of no clinical value.

Key Words: Aspirin • Plavix • Antiplatelets • Platelet receptors • Coronary intervention




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
J. Nappi
Benefits and limitations of current antiplatelet therapies
Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S5 - S10.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. S. Tweddell
Aspirin: A Treatment for the Headache of Shunt-Dependent Pulmonary Blood Flow and Parallel Circulation?
Circulation, July 17, 2007; 116(3): 236 - 237.
[Full Text] [PDF]

Home page
 CirculationHome page
J. S. Li, E. Yow, K. Y. Berezny, J. F. Rhodes, P. M. Bokesch, J. R. Charpie, G. A. Forbus, L. Mahony, L. Boshkov, V. Lambert, et al.
Clinical Outcomes of Palliative Surgery Including a Systemic-to-Pulmonary Artery Shunt in Infants With Cyanotic Congenital Heart Disease: Does Aspirin Make a Difference?
Circulation, July 17, 2007; 116(3): 293 - 297.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by Marshfield Clinic.